Nippon Shinyaku, Elixirgen Sign EXG-7001 DMD Option Deal
KYOTO, Japan, June 26, 2026 Nippon Shinyaku Co., Ltd. announced it has entered into an option agreement with Elixirgen...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
KYOTO, Japan, June 26, 2026 Nippon Shinyaku Co., Ltd. announced it has entered into an option agreement with Elixirgen...
